For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …

Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Background Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer
(NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage …

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with
previously treated, advanced microsatellite instability–high or mismatch repair–deficient …

PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …

Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus
(HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a …

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell
Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% - PMC Back to Top Skip to main …